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Chapter 1: INTRODUCTION
A drug includes all medicines intended for internal or external use for or
in the diagnosis, treatment, mitigation or prevention of disease or disorder in
human beings or animals, and manufactured exclusively in accordance with
the formulae mentioned in authoritative books.1
Pharmaceutical analysis is a branch of chemistry involving a process of
identification, determination, quantification, purification and separation of
components in a mixture or determination of chemical structure of
compounds. There are two main types of analysis – Qualitative and
Quantitative analysis.
Qualitative analysis is performed to establish composition of a
substance. It is done to determine the presence of a compound or substance
in a given sample or not. The various qualitative tests are detection of evolved
gas, limit tests, color change reactions, determination of melting point and
boiling point, mass spectroscopy, determination of nuclear half life etc.
Quantitative analysis techniques are mainly used to determine the
amount or concentration of analyte in a sample and expressed as a numerical
value in appropriate units. These techniques are based on suitable chemical
reaction and either measuring the amount of reagent added to complete the
reaction or measuring the amount of reaction product obtained the
characteristic movement of a substance through a defined medium under
controlled conditions, electrical measurement or measurement of
spectroscopic properties of the compound. 2
1.1 High Performance Liquid Chromatography
Chromatography is the method of separation that finds applications in
all branches of science. It was first invented by Russian Botanist Mikhail
Twsett. This technique was used separate various plant pigments like
chlorophylls and xanthophylls by passing solutions of these compounds
through a glass column packed with finely divided calcium carbonate. The
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separated species appeared as colored bands on the column hence the
name of the process (Greek chroma meaning “color” and graphein meaning
“writing”). 3
Chromatography is defined as a non- destructive procedure for
resolving multi-component mixture of trace, minor, or major constituents into
its individual fractions. In chromatography, the sample is dissolved in the
mobile phase which may be a gas, liquid, or a supercritical fluid. The
principle involved in HPLC is that when a mixture containing different
compounds is introduced into the mobile phase and allowed to flow over a
stationary phase, the individual compounds travel at different speeds and
get separated based on the relative affinities to the stationary phase and the
mobile phase. The compounds are separated based on the polarity of the
stationary phase and the mobile phase.
Chromatography is of various types based on the physical state of the
stationary and the mobile phase:
1. Solid - Liquid type: The stationary phase is a solid and the mobile
phase is a liquid. Ex: Thin layer chromatography, High performance
liquid chromatography (HPLC).
2. Liquid - Liquid type: The stationary phase is a liquid and the mobile
phase is also a liquid. Ex: Paper Chromatography, HPLC.
3. Liquid - Gas Type: The stationary phase is a liquid and the mobile
phase is a gas. Ex: Gas chromatography.
High Performance Liquid Chromatography is the most widely used of
all the analytical separation techniques. The reasons for its popularity are its
sensitivity, ready adaptability to quantitative determination, suitable for non-
volatile and thermally fragile species, wide applicability to variety of
substances such as amino acids, carbohydrates, nucleic acids, proteins,
hydrocarbons, terpenoids, pesticides, steroids, metal-organic species and
inorganic species. As high pressures (around 3000 psi) are used for the
separation of the analytes down the column, it is often termed as High
Pressure Liquid Chromatography. 4, 5, 6
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1.2 Types Of HPLC
HPLC is classified into various types
a) Based on polarity of stationary and mobile phase
 Normal Phase Chromatography
 Reverse Phase Chromatography
b) Based on the principle of separation
 Adsorption Chromatography
 Partition Chromatography
 Ion Pair Chromatography
 Size Exclusion Chromatography
 Chiral Phase Chromatography
c) Based on elution technique
 Isocratic Elution
 Gradient Elution
d) Based on scale of operation
 Analytical HPLC
 Preparative HPLC
1.2.1.a Based on the polarity of the stationary phase and the mobile phase,
it is of two types:
Normal Phase (NP) HPLC
In this type, the stationary phase is polar and the mobile phase is
non-polar, polar compounds are retained for a longer periods because of
more affinity towards the stationary phase, hence non-polar compounds
travel faster and are eluted first.
Reverse Phase (RP) HPLC
In this type, the stationary phase is non-polar and the mobile phase is
polar, non-polar compounds are retained for longer periods as they have
more affinity towards the stationary phase. Hence, polar compounds travel
faster and are eluted first. 3, 4, 5, 6
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Table 1.1: Types of HPLC based on polarity of stationary phase and mobile
phase.
1.2.1.b Based on the principle of separation, chromatography is divided into
various types,
Adsorption chromatography
It is one of the oldest types of chromatography. The principle involved
is adsorption. Adsorption is a surface phenomenon in which the separation
mechanism depends on the difference in the polarity of various drug
molecules. The more polar a molecule, the more strongly it will be adsorbed
by a polar stationary phase. Similarly the more non-polar a molecule, the
more strongly it will be adsorbed by a non-polar stationary phase. 7, 8
During a surface adsorption chromatography process, a competition for
stationary phase adsorption sites exists between the materials to be
separated and the mobile phase. In a mixture, molecules of low polarity spend
proportionally more time in the mobile phase than those molecules that are
highly polar, which are retained for a longer period of time. Therefore the
components of a mixture are eluted in order of increasing polarity. 9
Partition Chromatography
The principle involved is partition in which the solute molecules
distribute themselves between the mobile and the stationary phases. In
partition chromatography the stationary phase is a non-volatile liquid which is
held as a thin layer (or film) on the surface of an inert solid. The mixture to be
separated is carried by a gas or a liquid as the mobile phase. With the use of
liquid as mobile phases, there is a tendency for the stationary liquid phase to
Types Normal Phase Reverse Phase
Stationary phase Polar Non polar
Mobile phase Non polar Polar
Compound eluted first Non polar Polar
Compound eluted last Polar Non polar
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be removed or dissolved. Therefore, the stationary liquid phase has to be
chemically bonded to the solid bonding support such as silica gel, cellulose
powder, or kieselguhr (hydrated silica). The solute molecules in the mobile
phase move through the system at rates determined by their relative
solubilities in the stationary and mobile phases. 9, 10
Ion Exchange Chromatography
Ion Exchange Chromatography is based on the reversible interaction
between a charged protein and an oppositely charged chromatography
medium. Biomolecules such as proteins, peptides, nucleic acids  with even
small differences in net surface charge can be separated, and very high
resolution is obtained by choosing the optimal ion exchanger and separation
conditions. The net surface charge of a protein varies according to the
surrounding pH. Typically, when the pH is above its isoelectric point, a protein
will bind to a positively charged anion exchanger. Below its isoelectric point, a
protein will bind to a negatively charged cation exchanger.
Anion and cation exchangers are classified as strong or weak,
depending on how much the ionization state of the functional groups vary with
pH. A strong ion exchanger has the same charge density on its surface over
a broad pH range, whereas the charge density of a weak ion exchanger
changes with pH. The selectivity and the capacity of a weak ion exchanger
are different at different pH values. 11, 12
Size Exclusion Chromatography
This process is also known as Gel Permeation Chromatography. In this
method the mixture of compounds with various molecular sizes are separated
according to size or molecular weight. The stationary phase consists of a
porous cross-linked polymeric gel. The pores of the gel normally small and
exclude the larger solute molecules, but allows smaller molecules to enter the
gel, causing them to flow through a larger volume. This causes the larger
molecules to pass through the column at a faster rate than the smaller ones.
The components of a mixture therefore elute in order of decreasing size or
molecular weight. 9, 13
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Size Exclusion Chromatography is used extensively in the biochemical
industry to remove small molecules and inorganic salts from valuable higher
molecular weight products such as peptides, proteins and enzymes.
Chiral Phase Chromatography
In this type of chromatography, optical isomers are separated using
chiral stationary phases. Two approaches for chiral separation are available,
indirect, which utilizes derivatizing agents, and direct, which uses chiral
stationary phases or chiral mobile phase additives.
In the indirect method, a racemic mixture is made to react with a chiral
reagent to form a pair of diastereomers and then chromatographed using an
achiral column. Because diastereomers possess different physiochemical
properties, they can be separated in an achiral environment.
Direct separation of enantiomers on an achiral column using a chiral
mobile phase additive is applied only in HPLC.  In this method, enantiomeric
separation is accomplished by the formation of a pair of transient
diastereomeric complexes between racemic analyte and the chiral mobile
phase additive.  Chiral discrimination is due to differences in the stabilities of
the diastereomeric complexes, solvation in the mobile phase, and/or binding
of the complexes to the solid support.14
1.2.1.c Based on elution technique, chromatographic methods are of two
types,
Isocratic Elution
In this technique, the composition of the mobile phase is maintained as
constant throughout the process of separation. All the compounds in the
sample are eluted in a reasonable amount of time, by changing the ratio of
polar to non-polar compounds in the mobile phase during the sample run
while maintaining peak resolution. 15
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Gradient Elution
A steady change of the mobile phase composition during the
chromatographic run is called gradient elution. This is widely used technique
when a sample contains components of a wide range of polarities. For a
reverse phase gradient, the solvent starts out relatively polar and slowly
becomes more non-polar. The gradient elution offers the most complete
separation of the peaks, without taking much time. A sample containing
compounds of a wide range of polarities can be separated by a gradient
elution in a shorter time period without a loss of resolution in the earlier peaks
or excessive broadening of later peaks. 15, 16
Gradient elution also increases quasi-efficiency of the column. In the
isocratic elution, the longer a component is retained, the wider its peak. In
gradient elution, the tail of the peak is always under the influence of the
stronger mobile phase when compared to the peak front. Thus, molecules on
the tail of the chromatographic peak will move faster. This will tend to
compress zone and narrow the resultant peak. 16
1.2.1.d Based on the scale of operation, chromatography is of two types,
Analytical HPLC
In Analytical HPLC, quantitative and qualitative determination of a
compound is done. It is the most widely used technique. In this method, the
sample amount applied to the column is typically in the μg range or lower
quantities. The mass ratio of compound to the stationary phase on the column
is less than 1: 100000. Under these conditions good separations with sharp
and symmetrical peaks are achieved. Recovery of samples is not possible as
small quantities of the sample are used. 17
Preparative HPLC
In Preparative HPLC, isolation and purification of a product is done. It
is an expensive technique, when compared to the traditional purification
techniques like distillation, crystallization or extraction.
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Preparative HPLC is used for the isolation and purification of valuable
products in the chemical and pharmaceutical industry as well as in
biotechnology and biochemistry. It starts in the µg range for isolation of
enzymes in biotechnology (micro purification). For identification and structure
elucidation of unknown compounds in synthesis or natural product chemistry it
is necessary to obtain pure compounds in amounts ranging from one to a few
milligrams. Larger amounts, in gram quantity, are necessary for standards,
reference compounds and compounds for toxicological and pharmacological
testing. Industrial scale or production scale preparative HPLC, that is, kg
quantities of compound, is often done nowadays for valuable pharmaceutical
products. 17
1.3 Instrumentation of HPLC
The main components of HPLC are as given below and are
schematically represented in Fig 1.1
1. Solvent Reservoir
2. Solvent Delivery System (Pump)
3. Injection Port/ Autosampler
4. Column
5. Detector
6. Data Acquisition system
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Fig. 1.1: Schematic diagram of instrumentation of HPLC. 18
1.3.1 Solvent Reservoir
Solvent Reservoirs are used to store mobile phase. Scott Duran bottles
are commonly used as solvent reservoirs. The solvent reservoir must be
made of inert material such as glass and must be smooth so as to avoid
growth of microorganisms on its walls. It may be transparent or can be amber
colored. A graduated bottle gives a rough estimate of mobile-phase volume in
the bottle. Solvent reservoirs are placed above HPLC system (at higher level)
in a tray. They should never be kept directly above the system as any spillage
of solvent on the system may damage electronic parts of HPLC.
1.3.2 Solvent Delivery System (Pump)
Pumps are an important component of the HPLC system. It delivers a
constant flow of mobile phase such that the separation of components of
mixture takes place in a reasonable time. There are different types of pumps:
a) Reciprocating Pumps
b) Displacement Pumps
c) Pneumatic Pumps
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In reciprocating pumps, a motor driven reciprocating piston controls the
flow of mobile phase with the help of two ball check valves that opens and
closes with the piston movement. The flow is thus not continuous and as
damping of flow is necessary, it is accomplished using pulse dampers which
are a long coiled capillary tube. Reciprocating pumps are most widely used in
HPLC systems.
Displacement pumps, also known as syringe pump is  composed of a
one directional motor driven plunger that pushes the mobile phase present in
a syringe like chamber. The volume of displacement pumps is limited. A
constant flow rate is usually obtained with syringe like pumps.
Pneumatic pumps are the simplest where the mobile phase is pushed
out of the mobile phase container by the pressure of a pressurized gas. The
flow is dependent on the back pressure of the column and usually the flow is
limited to pressures below 2000 psi. 20
1.3.3 Injection Port or Auto sampler
The Sample Injector enables small liquid samples to be injected into
the HPLC system without the sample passing through the pump. The function
of the injector is to place an accurate volume of the sample into the high-
pressure flow of the mobile phase so that the sample enters the column as a
homogeneous, low-volume plug. It is of two types; manual injector or an auto
injector. Injection is done through specially designed 6-port rotary injection
valve or a Rheodyne valve as shown in Fig 1.5. The sample is introduced at
atmospheric pressure by a syringe into a constant volume loop. In the LOAD
position the loop is not in the path of the mobile phase. By rotating to the
INJECT position the sample in the loop is moved by the mobile phase stream
into the column. It is important to allow some sample to flow into waste from
loop so as to ensure there are no air bubbles in the loop and previously used
sample is completely washed out to prevent previous sample effects. The
sample loading can be varied by part filling of the loop or by changing the loop
volume. 21, 22
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Automatic injection improves laboratory productivity and eliminates
personal errors. Present day advanced HPLC systems are equipped with an
auto injector along with an auto sampler. The software programs help filling of
the loop and delivery of the sample to the column. The computer controls the
sequence of samples for injection from vials kept in numbered positions of the
auto sampler. It is important to adopt precautions to ensure consistency of
results. 22
Fig. 1.2: Flow Path of a Manual Injector. 23
1.3.4 HPLC Column
The HPLC column is referred to as the heart of the process. The
stationary phase of the column is used in separating the individual fractions of
a sample mixture by using various physical and chemical parameters.
Columns for analytical HPLC are of various sizes ranging from 10 - 25 mm in
length and 2.6 – 4.6 mm internal diameter (i.d). Columns for preparative
HPLC are in size range of 50 – 250 mm long and i.d greater than 4.6 mm. The
columns are generally constructed of stainless steel SS-316 grade to cope
with high back pressure (caused by the small particles of the stationary
phase) and are glass lined to prevent metal catalysis of solvent- solute
reactions at high column pressures (due to force of pumping of the mobile
phase through the columns). Columns made of glass are used for the
separation of Biomolecules and columns made of PEEK polymer are
biocompatible and chemically inert to most solvents. 24
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Stationary phase
Separation of pharmaceuticals is usually achieved by partition of
compounds in the test solution between the mobile and the stationary phases.
HPLC systems consisting of polar stationary phases and non-polar mobile
phases are described as normal-phase chromatography; those with non-polar
stationary phases and polar mobile phases are called reversed-phase
chromatography.
There are many types of stationary phases used in HPLC including:
- Unmodified silica, alumina, or porous graphite, used in normal-phase
chromatography, where separation is based on differences in
adsorption;
- A variety of chemically modified supports prepared from polymers,
silica, or porous graphite, used in reverse-phase HPLC, where
separation is based principally on partition of the molecules between
the mobile phase and the stationary phase;
- Resins or polymers with acid or basic groups, used in ion-exchange
chromatography, where separation is based on competition between
the ions to be separated and those in the mobile phase;
- Porous silica or polymers, used in size-exclusion chromatography,
where separation is based on the relative molecular mass of the
molecules.
Most separations are based on partition mechanisms using chemically
modified silica as the stationary phase and polar solvents as the mobile phase
(reverse-phase HPLC). The surface of the support, e.g. the silanol groups of
silica, is reacted with various silane reagents to produce covalently bonded
silyl derivatives covering a varying number of active sites on the surface of the
support. The nature of the bonded phase is an important parameter for
determining the separation properties of the chromatographic system.
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For the separation of enantiomers, special chemically modified
stationary phases (chiral chromatography) are available, e.g. cyclodextrins,
albumins, etc.
Generally, silica-based reverse-phase columns are generally
considered to be stable in mobile phases with an apparent pH in the range 2.0
- 8.0, but the column manufacturer's instructions should be consulted before
using the column. Columns containing particles of polymeric materials such
as styrene divinyl benzene copolymer are stable over a wider pH range.
For analytical separations the particle size of the most commonly used
stationary phases varies between 3 μm and 10 μm. The particles may be
spherical or irregular, of different porosities and specific surface area. In the
case of reversed-phase, the extent of bonding of the stationary phase is
expressed as the carbon-loading. Furthermore, stationary phases may be
"end-capped", i.e. the number of residual silanol groups is reduced by
methylation. These parameters contribute to the chromatographic behavior of
a particular stationary phase. Tailing of peaks, particularly for basic
substances, can occur when residual silanol groups are      present. 25
1.3.5 Detector
A detector in the HPLC system measures the compounds after their
separation from the column. The detector selected should be capable of
responding to changes in the concentration of all the components in the
sample with adequate sensitivity even to measure trace amounts. Basically
there are two types of detectors: bulk property and solute property detectors.
The bulk property detectors, function on some bulk property of the eluent such
as refractive index (RI) and is not suitable for gradient elution and are usually
less sensitive than solute property detectors. Solute property detectors
perform by measuring a physical or chemical property that is specific to the
solute. Detectors should have high linear dynamic range and should give
faster response. The various detectors used and their applications are given
in Table 1.2
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Table 1.2: Commonly used detectors and their application. 26, 27
Detector Analytedetected
Solvent
requirement
s
Uses
UV-Visible
Any
compounds
with
chromophor
e
Non UV
absorbing
solvents
Wavelength at which maximum
absorption occurs can be
selected. Has a high degree of
selectivity and is useful for many
applications.
Photo
diode array
(PDA)
detector
Any
compound
with
chromophor
e
Non UV
absorbing
solvents
Detects an entire spectrum
simultaneously. Useful for
analysis of related substances
and impurities.
Fluores-
cence
Fluorescent
compounds
Non UV
absorbing
solvents
Highly selective and sensitive.
Wavelength at which
fluorescence occurs is selected.
Often used to analyze
derivatised samples after
treatment with DANSYL chloride
to form fluorescent compounds.
Refractive
index (RI)
Compound
with a
different RI
to that of the
mobile
phase
Cannot run
mobile phase
gradients
Virtually it is a universal detector
but has limited sensitivity. Used
for the detection of sugars.
Conduct-
ivity
Charged or
polar
compounds
Mobile phase
must be
conducting
Excellent detector for ion
exchange methods.
Electro-
chemical
Readily
oxidized or
reduced
compounds
Mobile phase
must be
conducting
Very sensitive and selective.
Used for detection of Biological
compounds.
Evaporativ
e light
scattering
detector
(ELSD)
All
compounds
are detected
virtually
Volatile
solvents and
volatile
buffers must
be used.
Universal detector, Highly
sensitive but not selective. But
can be use for gradient analysis.
Used for the detection of lipids,
sugar and high molecular weight
analytes.
Optical
rotation
detector
Optically
active
compounds
Mobile phase
should be an
asymmetric
environment
Detects R and L type of isomers
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Mass
Spectro-
meter (MS)
Broad range
of
compounds
Volatile
solvents and
volatile
buffers must
be used
Compounds are detected by
difference in mass numbers.
Highly sensitive and a two
dimensional analytical tool. Used
to quantify low detection limit of
molecular and elemental
compounds
1.3.6 Data Collection devices
Signals from the detector may be collected on chart recorders or
electronic integrators that vary in complexity and in their ability to process,
store and reprocess chromatographic data. The data storage capacity of
these devices is usually limited
Modern data stations are computer based and have a large storage
capacity to collect process and store data for possible subsequent
reprocessing. Analytical reports can often be customized to the needs of the
analyst.
Integration of peak areas and the setting of threshold levels are not
normally problematic in an assay since the peak of the substance to be
analyzed should be free of interference. However, in a test for impurities, the
selection of the peak area integrator parameters becomes very important,
particularly when baseline separations are not always attainable. If baseline
separations cannot be obtained, valley-to-valley integration should be
employed
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METHOD DEVELOPMENT AND VALIDATION
1. 4 Introduction to Method Development
The number of drugs introduced into the market is increasing every
year. These drugs may be either new entities or partial structural modification
of the existing one. Often a time lag exists from the date of introduction of a
drug into the market to the date of its inclusion in pharmacopoeias. This
happens because of the possible uncertainties in the continuous and wider
usage of these drugs, reports of new toxicities (resulting in their withdrawal
from the market), development of patient resistance and introduction of better
drugs by competitors. Under these conditions, standards and analytical
procedures for these drugs may not be available in the pharmacopoeias. It
becomes necessary, therefore to develop newer analytical methods for such
drugs. 28, 29
Analytical methods should be used within good manufacturing practice
(GMP) and good laboratory practice (GLP) environments, and must be
developed using the protocols set out in the International Conference on
Harmonization (ICH) guidelines (Q2A and Q2B). 30, 31
Method development is a continuous process that progresses in
parallel with the evolution of the drug product. The goal and purpose of the
method should reflect the phase of drug development. During early drug
development, the methods may focus on API behavior. They should be
suitable to support preclinical safety evaluations, pre-formulation studies, and
prototype product stability studies. As drug development progresses, the
analytical methods are refined and expanded, based on increased API and
drug product knowledge. The methods should be robust and uncomplicated,
while still meeting the appropriate regulatory guidelines. Scouting experiments
are frequently performed during method development to establish the
performance limits of the method, prior to formal validation experiments.
These may include forced degradation studies, which are an integral part of
development of a stability-indicating method. API is typically subjected to
degradation by acid, base, peroxide, heat, and light. This allows for a
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determination of the capability of the method to separate and quantify
degradation products, while providing insight into the main mechanisms of
degradation. Once a stability-indicating method is in place, the formulated
drug product can then be subjected to heat and light in order to evaluate
potential degradation of the API in the presence of formulation excipients. 32
1.4.1 Need for the Development of a New Method
Several reasons are available for the development of a new method of
analysis.
 There may not be a suitable method for a particular analyte in the
specific sample matrix.
 Existing methods may be too erroneous, artefact and/or contamination
prone, or they may be unreliable (having poor accuracy or precision).
 Existing methods may be too expensive, time consuming, or energy
intensive, or they may not be easily automated.
 Existing methods may not provide adequate sensitivity or analyte
selectivity in samples of interest.
 Newer instrumentation and techniques may have evolved that provide
opportunities for improved methods, including analyte identification or
detection limits, greater accuracy or precision, or better return on
investment.
 There may be a need for alternative method to confirm, for legal or
scientific reasons, analytical data originally obtained by existing
methods. 33
1.5 Method Development Using HPLC
In method development, an attempt to select the best chromatographic
conditions like the best column, the best mobile phase, the detection
wavelength etc. to be used for routine analysis of any drug is done. For the
method development by HPLC method some information about the sample is
very essential i.e. number of components present in the sample, pKa values
of different components, UV-Visible Spectra of each analyte, solubility in
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different solvents, concentration range of each component, nature of sample
etc. Prior to method development there must be some technical information
i.e. chromatography method selection according to the sample properties, the
sample when analyzed with HPLC, the condition where all compounds elute
in a reasonable time, optimization of HPLC method with regard to analysis
time, resolution, selectivity and sensitivity. 28
1.5.1 Analyte Standard Characterization
All the information about the analyte is gathered regarding the
structure, physical and chemical properties, toxicity, purity, hygroscopicity,
solubility and stability. The availability of the 100% pure standard analyte is
determined along with its storage and disposal information. If multiple
components are to be analyzed in a sample matrix, the number of
components to be analyzed is noted and the availability of the standard for
each component is checked. 29, 33
1.5.2 Literature Search and Prior Methodology
The available literature is searched for all types of information related
to the analyte. Availability of information regarding the synthesis, physical and
chemical properties, solubility or relevant analytical methods is determined.
Books, periodicals, regulatory agency compendia, such as IP, USP/NF, BP
etc. should be referred. Chemical Abstracts Service (CAS) automated/
computerized literature searches also should be used.
Information pertaining to prior analytical work on the analyte has to be
determined within the company and compile the available data, results,
reports, memos and publications. 33
1.5.3 Choosing a Suitable Method
Using the available literature and previous methodology, the methods
are adapted and modified. Sample preparation and instrument conditions are
adopted to make use of the latest methods and instrumentation.
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If no previous methods exist for the analyte in the literature, work from
analogy to investigate compounds that are similar in structure and properties.
Usually a compound with analytical method exists that is similar to the analyte
of interest. 33
1.5.4 Optimization
a) Choice of method
The most commonly used chromatographic methods are normal phase
chromatography, reverse phase chromatography, reverse phase ion-pair
chromatography and ion-exchange chromatography. In the selection of
suitable chromatographic method for organic compounds, first reversed phase
should be tried, if not successful, normal phase should be tried, then reverse
phase ion-pair chromatography should be tried, ion-exchange
chromatography at the end. 29
b) Choice of Mobile Phase
In reversed phase chromatography the selection of mobile phase is
very important for the analysis of the drug. We can use acetonitrile frequently
as it is suitable for the entire UV range, methanol and Isopropanol are not
suitable below wavelength of 210 nm, acetic acid is suitable above a
wavelength of 240 nm, for the preparation of buffers, both K2HPO4 and
KH2PO4 can be used in entire UV range, freshly distilled THF is suitable for
HPLC above a wave length of 240 nm, TEA is suitable above 240 nm,
ammonium acetate can be used above 215 nm, EDTA can be used in entire
UV range, sodium phosphate is suitable above 210 nm. 29
The organic phase concentration required for the mobile phase can be
estimated by gradient elution method. For aqueous sample mixtures, the best
way to start is with gradient reversed phase chromatography. Gradient can be
started with 10% organic phase in the mobile phase and organic phase
concentration (Methanol & Acetonitrile) can be increased up to 100% within
20 - 60 min. Separation can then be optimized by changing the initial mobile
phase composition according to the chromatogram obtained from preliminary
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run. The initial mobile phase composition can be estimated on the basis of
where the compounds of interest were eluted, at what mobile composition.
Changing the polarity of the mobile phase can alter the elution of drug
molecules. The elution strength of a mobile phase depends upon its polarity,
the stronger the polarity, higher is the elution. Ionic samples (acidic or basic)
can be separated, if they are present in un-dissociated form. Dissociation of
ionic samples may be suppressed by proper selection of pH.
The pH of the mobile phase has to be selected in such a way that the
compounds are not ionized. If the retention times are too short, the decrease
of the organic phase concentration in the mobile phase can be in steps of 5%.
If the retention times are too long, an increase in 5% steps of the organic
phase concentrations is needed.
When separating acid or bases, buffered mobile phase is required to
maintain consistency in retention time and selectivity. Buffered salts reduce
peak tailing for basic compounds by effectively masking silanol groups and
also reduce potential ion-exchange interactions with a protonated silanol
groups. As potassium is a stronger counter ion than sodium, it provides
improved results compared to sodium (Na+). Potassium phosphate is used for
preparation of buffers of various pH. If band tailing is observed for basic
amphoteric compounds few drops of diluted triethylamine or ammonium
acetate is added, for acidic or amphoteric compounds, few drops of diluted
triethylamine or ammonium acetate is tried. For neutral compounds, the
aqueous eluent used in method development is water, for weak to medium
acidic compounds, 100 mM H3PO4 buffer of pH 2.3, for weak to medium basic
or acidic compounds in ionized form 100 mM H3PO4 buffer of pH 4.0, 50 mM
H3PO4 buffer of pH 7.5 are used. Unknown sample should be analyzed first
with water, then with an acidic and a neutral buffer.
During mixing of the solvents in the preparation of mobile phase, the
difference in partial pressure of the individual solvent at a ratio they are to be
combined should be considered. The solvent system must be miscible with
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the previously used mobile phase, if not intermediate solvent may be used,
the one that is miscible with previous mobile phase and new mobile phase.
c) Choice of Column
Columns being the heart of HPLC for optimum separation, Stable, high
performance column with good selectivity, efficiency is essential requirement
for rugged and reproducible method. These characteristics are dependent on
the columns manufacturer’s production of good quality columns and packing
materials.
Column length
 Longer columns are chosen for increased resolution.
 Shorter columns are chosen for shorter analysis time, lower back
pressure, fast equilibration and less solvent consumption.
Column internal diameter
 Wider diameter columns are chosen for greater sample loading.
 Narrow columns are chosen for more sensitivity and reduced mobile
phase consumption.
Particle shape
 Columns with spherical particle shapes are preferred when lower back
pressure column stability and greater efficiency is required.
 Columns with irregular particle shapes are preferred when large
surface area and high capacity is required.
Particle size
 Columns with small particle size of 3 - 4 μm are preferred for complex
mixtures with similar components. Combination of a short column
(10 - 50 mm) with small particle size is used for fast, high resolution
separations.
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 Columns with larger particle size of 5 – 10 μm are preferred for
structurally different compounds.
 Columns with large particle of 15 – 20 μm are used for preparative
separations.
Surface area
 Columns with high surface area packing are selected for more
capacity, greater resolution and longer retention.
 Columns with low surface area packing are selected for quicker
equilibration time.
Carbon load
 Columns with high carbon load are chosen for greater column
capacities and resolution.
 Columns with low carbon load for faster analysis time.
End capping
 Columns with end capped packing are selected to eliminate
unpredictable secondary interactions with base material
 Columns with non-end capped packing are selected for selectivity
differences for polar compounds by controlling secondary interactions.
29
d) Choice of Detector
Detectors are eyes of the liquid chromatography system and measure
the compounds after their separation on the column. Selected detector should
be capable of responding to change in concentrations of all the components in
the sample with adequate sensitivity even to measure trace substances. The
detectors must have certain characteristics i.e. high sensitivity, higher linear
dynamic range, application to most of the solutes, does not contribute to band
broadening, non-destructive, faster response. 29
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1.5.5 Further Optimization
After the selection of a suitable method, mobile phase, column and
detector, further optimization can be done to obtain a well developed method.
For shorter analysis time
 Change to isocratic method. The suitable mobile phase composition is
estimated from the gradient run.
 Use of shorter column, if proper resolution is obtained.
For better resolution
 Use of longer column.
 Use of stationary phase with smaller particles (3 – 4 μm).
For better selectivity and sensitivity
 Other stationary phases e.g. phenyl, CN etc.
 pH control with ion-forming compounds
 Use of methanol or THF instead of acetonitrile.
 Detection at the absorption maximum of the substance
 All factors which leads to narrower and higher peaks as gradient
elution, smaller particle, micro bore columns. 35
Fig 1.3: Outline of the process involved in method development
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1.6 Parameters Affecting Changes in Chromatograph
The various parameters affecting the changes in chromatographic conditions
are
1. Flow rate
2. Temperature
3. pH
4. Ion pair reagent
5. Column efficiency
6. Capacity factor
7. Resolution
8. Retention time
9. Peak asymmetry
1.6.1 Effect of Flow Rate
The efficiency of a HPLC column varies with flow rate. It is sometimes
useful and readily utilized to increase the resolution. A faster flow rate of the
eluent minimizes the time required to run a column and thereby minimizes
diffusion, resulting in a better separation (less band broadening). However,
the maximum flow rate is limited because a finite time is required for analyte
to equilibrate between stationary phase and mobile phase. A slower flow rate
will decrease the column back pressure and a corresponding increase in the
run time is observed. 36, 37
Table 1.3: Flow rates for column with different internal diameter. 36
Internal diameter
of column (mm)
Standard flow
rate (μL/ min)
4.6 1000
2.1 200
1.0 50
0.30 4
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1.6.2 Effect of Temperature
Elevated temperatures decrease viscosity and increase solubility and
diffusivity. Retention, peak shape, column efficiency, and total analysis time
are affected by temperature because both the thermodynamics and kinetics of
adsorption processes are functions of temperature. Additionally, temperature
control results in improved reproducibility. In liquid chromatography
temperature is used in the optimization of a separation. At higher
temperature, peaks will be sharper and elute earlier. System pressure is
affected by temperature. The viscosity of the mobile phase decreases with
increasing temperature. For example if the HPLC system pressure is too high
for a given solvent system temperature of the column may be raised to 40 0C
or even 60 0C. Higher temperature will lead to a shorter column lifetime and
some columns may not be able to tolerate 60 0C. The combination of smaller
diameter packing with shorter column lengths at elevated temperatures
facilitates efficient and fast separations, meeting the high throughput
performance requirements of the pharmaceutical industry. 38, 39
1.6.3 Role of pH
For some preparations the effect of changing pH is minimal. However
for acids and bases, a small change in pH is significant. Changing the pH
changes the degree of ionization of molecules in solution, affecting polarity of
the solution thereby changing the retention times in an HPLC separation. In a
sample mixture, the retention time of the components of the mixture are also
changed to different extents. Hence it affects the degree of selectivity, where
the peaks become further apart or at a particular pH they may co-elute and
then the peak elution order will change. Selection of a proper buffer pH is
necessary to reproducibly separate ionizable compounds by RP-HPLC.
Selection of an improper pH for ionizable analytes leads to asymmetric peaks
that are broad, tall or split.
During the selection of a buffer, pKa of the analyte should be
considered. A buffer with 2 pH units above or below pKa of the analyte is
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recommended for a good peak shape. From Henderson- Hasselback
equation,
It can be determined that 99% of the analyte is in a single form, Good
peak shape is possible only when an analyte is in a single form. 40, 41, 42
1.6.4 Role of Ion-Pair Reagent
Most of these compounds are ionic or polar; hence the use of reversed
phase-high performance liquid chromatography (RP-HPLC) is somewhat
restricted. Initially when deciding to select RP-HPLC or RP-HPLC with ion-
pairing, the nature of the analyte of interest is considered. If the sample is
neutral, RP-HPLC is used first; and if the sample is ionic, RP-HPLC with ion
pairing is used. Thus RP-HPLC and RP-HPLC with ion pairing are similar
except that the latter consists of an ion-pair reagent in the mobile phase to
improve the selectively of ionic samples. The ionic pair reagents are large
ionic molecules having a charge opposite to the analyte of interest, as well as
a hydrophobic region to interact with the stationary phase. The counter-ion
combines with the ions of the eluent, becoming ion pairs in the stationary
phase. This results in different retention, thus facilitating separation of
analytes.
The use of an ion-pair reagent is suggested only when separation is
not adequate with reversed-phase HPLC. This is because using an ion-pair
reagent introduces additional experimental parameters that need to be
controlled, such as selection of a suitable ion-pair reagent to use and its
concentration. Because of this added variable, reversed-phase HPLC should
be utilized on any ionic analyte first before trying ion-pair reversed–phase
HPLC. The approach used in RP-HPLC to separate charged analytes is ionic
suppression. This technique is based on the pH adjustment of the mobile
phase to result in a non-ionized analyte. However, this requires extensive
pH = pKa + log ([A-]/ [HA])
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method development and is only suitable for single compounds or simple
mixtures where the pKa’s of the analytes lie close together. 43
1.6.5 Column Efficiency (N)
The efficiency of a chromatographic column is given terms of number
of theoretical plates (plate number), N
Where, tr- retention time measured from the time of injection, w- peak width
peak width obtained by drawing tangents to the sides of the Gaussian curve
at the inflection points and extrapolating the tangents to intercept the baseline
as in fig 2.3
Efficiency of the column is also expressed as height equivalent to
theoretical plate, (or plate height) HETP (or h)
Where, L- length of the column,
N- number of theoretical plates. 4, 29, 44
Fig. 1.4: Pictorial Representation of number of theoretical plates. 44
= 16
ℎ=
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1.6.6 Capacity Factor (k’)
It is measure of the position of a sample peak in the chromatogram,
being specific for a given compound, a parameter which specifies the extent
of delay of substance to be separated.
Where, tr– retention time of the solute, tm – retention time of the unretained
compound by the column packing. Fig 2.4 shows capacity factor of a solute.
k’ depends at stationary phase, mobile phase, temperature and quality
of column packing. For good chromatographic performance with isocratic
separation, k’ value should be in the range of 1-10. If k’ < 1.0, the bands are
inadequately separated from excessively unretained material, if k’ > 10
separation takes too long and bands broadened, if k’ > 30, satisfactory
isocratic separation using present column and mobile phase is not obtained
and gradient elution should be tried. 4, 29, 44
Fig.1.5: Pictorial representation of capacity factor. 44
1.6.7 Resolution (Rs)
The ability of the column to separate two solutes. In a chromatogram it
is the distance of separation of two peaks.
= −
= −0.5( − )
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Where,tr1 ,tr2 – retention time of two immediately adjacent peaks,
w1, w2 – peak widths of two immediately adjacent peaks as shown in fig 2.5.
4, 29, 44
Fig.1.6: Pictorial Representation of Resolution. 44
1.6.8 Selectivity factor (α) / Relative Retention
This describes the relative position of two adjacent peaks. Ideally, it is
calculated using the capacity factor because the peaks separation depends
on the components interaction with the stationary phase.
Where,
k’a, k’b– capacity factors of peak a and peak b respectively.
The value of the separation factor is always greater than unity. The
separation factor is also identical to the ratio of the corresponding distribution
constants. If the capacity factor is used, the separation factor should be
consistent for a given column, mobile phase composition and specified
temperature, regardless of the instrument used. 4, 29, 44 Fig 2.6 shows a
pictorial representation of measurement of selectivity factor
= ′′
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Fig.1.7: Pictorial representation of selectivity factor. 44
1.6.9 Peak Asymmetry (As)
It is also known as tailing factor. The asymmetry factor for a peak can be
calculated using the following formula.
Where, W0.05– peak width at 5% height from the base line,
f – distance between maximum and leading edge of the peak as in Fig 2.7
It is also calculated from
Where, b - distance from the point at peak maxima to the trailing edge,
a – distance from the leading edge of the peak to the peak maxima (both
measured at 10% height of the baseline) as shown in Fig 2.8. 29, 45
Fig. 1.8: Pictorial representation of peak asymmetry. 44
= .2
=
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Fig.1.9: Pictorial representation of peak asymmetry. 44
1.7 Introduction to Method Validation
Validation is an integral part of quality assurance; it involves the
systematic study of systems, facilities and processes aimed at determining
whether they perform their intended functions adequately and consistently as
specified. Validation in itself does not improve processes but confirms that the
processes have been properly developed and are under control. 45
Method validation is defined as the process of proving (through
scientific studies) that an analytical method is acceptable for its intended use.
To ensure compliance with quality and safety standards, the United States,
Europe, Japan, and other countries have published compendia, or
pharmacopeias, that describe official test methods for many marketed drug
products. For example, analytical methods found in United States
Pharmacopeia (USP) are legally recognized analytical procedures under
section 501 (b) of the Federal Food, Drug, and Cosmetic Act. For these
compendia methods, USP provides regulatory guidance for method validation.
In addition, validation of analytical methods is covered by the United States
Code of Federal Regulations (CFR). A great deal of effort has been devoted
to the harmonization of pharmaceutical regulatory requirements in the United
States, Europe, and Japan. As part of this initiative, the International
Conference on Harmonization (ICH) has issued guidelines for analytical
method validation. The recent FDA methods validation draft guidance
documents as well as U.S. both refer to ICH guidelines. 46
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The required validation parameters, also termed analytical
performance characteristics or analytical figs of merit. Methods should be
validated or revalidated
 Before their introduction and routine use;
 Whenever the conditions change for which the method has been
validated, e.g., instrument with different characteristics.
 Wherever the method is changed and the change is outside the
original scope of the method. 45
The validation of analytical procedures is directed to the four most common
types of analytical procedures: Identification tests; Quantitative tests for
impurities' content; Limit tests for the control of impurities; Quantitative tests of
the active moiety in samples of drug substance or drug product or other
selected component(s) in the drug product. 30
1.8 Method Validation (ICH Guidelines)
1. Accuracy,
2. Precision,
 Repeatability,
 Intermediate precision.
3. Specificity / Selectivity,
4. Limit of Detection,
5. Limit of Quantitation,
6. Linearity,
7. Range,
8. Robustness,
9. System Suitability.
The validation terminology in ICH guidelines differ from the validation
given in USP with two exceptions. Ruggedness is not included in ICH
guideline and treats system suitability as a part of method validation, whereas
the USP considers it in a separate chapter.
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1.8.1 Accuracy
The accuracy of an analytical procedure expresses the closeness of
agreement between the value which is accepted either as a conventional true
value or an accepted reference value and the value found. Accuracy should
be established across the specified range of the analytical procedure. 32
Accuracy is measured as the percentage of the analyte recovered by
assay, spiking samples in a blind study.
Accuracy studies for drug substance and drug product are
recommended to be performed at the 80, 100 and 120% levels of label claim
as stated in the Guidelines for Submitting Samples and Analytical Data for
Methods Validation
Accuracy should be assessed using a minimum of 9 determinations
over a minimum of 3 concentration levels covering the specified range (e.g., 3
concentrations /3 replicates each of the total analytical procedure). Accuracy
should be reported as percent recovery by the assay of known added amount
of analyte in the sample or as the difference between the mean and the
accepted true value together with the confidence intervals. 33, 34, 35
The acceptance criterion for accuracy is the Relative Standard
Deviation (RSD) for all the recovery values should not be more than 2.0%.
1.8.2 Precision
The precision of an analytical procedure expresses the closeness of
agreement (degree of scatter) between a series of measurements obtained
from multiple sampling of the same homogeneous sample under the
prescribed conditions. Precision may be considered at three levels:
repeatability, intermediate precision and reproducibility. 32
The precision of an analytical procedure is usually expressed as the
variance, standard deviation or coefficient of variation of a series of
measurements.30, 31, 32
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The relative standard deviation (RSD) for the assay of six sample
preparations should not be more than 2.0%.
1.8.3 Specificity
Specificity is the ability to assess accurately the analyte in the
presence of components which may be expected to be present in the sample
matrix. Typically these might include impurities, degradants, matrix, etc. it is a
measure of the degree of interference from such other things such as other
active ingredients, excipients, impurities, and degradation products, ensuring
that a peak response is due to a single component only. 32
Specificity is divided into two separate categories: identification and
assay/ impurity tests. For identification purpose, specificity is demonstrated by
the ability to discriminate between compounds of closely related structures or
comparison to a known reference standard. For assay/ impurity tests,
specificity is demonstrated by the resolution of the two closely eluting
compounds. These compounds are usually the major component or the active
ingredient and an impurity. 30, 31, 32
1.8.4 Limit of Detection (LOD)
The detection limit of an individual analytical procedure is the lowest
amount of analyte in a sample which can be detected but not necessarily
quantitated as an exact value. It is a limit test that specifies whether or not an
analyte is above or below a certain value.
It is expressed as a concentration at a specified signal to noise ratio
usually a 2 or 3-to-1 ratio. Two other method can also be used to determine
LOD: Visual non-instrumental methods and a means of calculation: Visual
non-instrumental methods may include techniques such as thin-layer
chromatography (TLC) or titrations. LODs may also be calculated based on
the standard deviation (SD) of the response and the slope (S) of the
calibration curve at levels approaching the LOD according to the formula:
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Where,
SD- standard deviation
S- Slope
The standard deviation of the response can be determined based on
the standard deviation of the blank, on the residual standard deviation of the
regression line, or the standard deviation of y-intercepts of regression lines.
The method used to determine LOD should be documented and supported,
and an appropriate number of samples should be analyzed at the limit to
validate the level. 30, 31, 32
1.8.5 Limit of Quantitation (LOQ)
The limit of quantitation (LOQ) is defined as the lowest concentration of
an analyte in a sample that can be determined with acceptable precision and
accuracy under the stated operational conditions of the method.
The ICH has recognized the 10-to-1 signal –to-noise ratio as typical,
and as for LOD, lists the same two additional options that can be used to
determine LOQ: visual non-instrumental methods and a means of calculation.
The calculation method is again based on the standard deviation (SD) of the
response and the slope (S) of the calibration curve according to the formula,
Where,
SD- standard deviation
S- Slope
Again, the standard deviation of the response can be determined
based on the standard deviation of the blank, on the residual standard
deviation of the regression line, or the standard deviation of y-intercepts of
regression lines. As with LOD, the method used to determine LOQ should be
= 3.3
= 10
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documented and supported, and an appropriate number of samples should
be analyzed at the limit to validate the level. 30, 31, 32
1.8.6 Linearity and Range
Linearity is the ability of the method to elicit test results that are directly
proportional to analyte concentration within a given range. Linearity is
generally reported as the variance of the slope of the regression line.  Range
is the (inclusive) interval between the upper and lower levels of analyte that
have been demonstrated to be determined with precision, accuracy, and
linearity using the method. The range is normally expressed in the same units
as the test results obtained by the method.
A minimum of five concentration levels, along with certain minimum
specified ranges are to be determined. For assay tests, the minimum
specified range is 80-120% of the target concentration. For impurity tests, the
minimum range is from the reporting level of each impurity to 120% of the
specification. 30, 31, 32
The relationship between the concentration (in %) of drug in sample
and area of should be linear in the specified range and the correlation should
not be less than 0.9.
1.8.7 Robustness
Robustness is the capacity of a method to remain unaffected by small
deliberate variations in method parameters. The robustness of a method is
evaluated varying method parameters such as percent organic solvent, pH,
ionic strength, or temperature and determining the effect (if any) on the
results of the method. 30, 31, 32
The RSD for the assay of drugs in a sample under deliberately
modified chromatographic conditions should not be more than 2.0%.
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1.8.8 System Suitability
System suitability tests are an integral part of gas and liquid
chromatographic methods. They are used to verify that the resolution and
reproducibility of the chromatographic system are adequate for the analysis to
be done. The tests are based on the concept that the equipment, electronics,
analytical operations and samples to be analyzed constitute an integral
system that can be evaluated as a whole. 47
System suitability is the checking of a system to ensure system
performance before or drying the analysis unknowns. Parameters such as
plate count, tailing factor, resolution and reproducibility (% RSD retention time
and area for repetitive injections) are determined and compared against the
specifications set for the method. These parameters are measured during the
analysis of a system suitability sample that is a mixture of main components
and expected by-products. 32
Table 1.4: Acceptance Limits for System Suitability Test. 32
Parameter Limit
Capacity Factor k’ > 2
Injection precision RSD < 1% for n ≥ 5
Resolution Rs > 2
Tailing factor As ≤ 2
Theoretical plates N > 2000
1.9 Definitions and Formulas Used in Method Validation
1.9.1 Mean/ Average (xi)
The average result (ā) is calculated by summing the individual results
and dividing the sum by the number (n) of individual values.
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Where, x1, x2, x3.. = Values of individual results
n = Number of individual results
1.9.2 Standard Deviation (SD)
It is the root mean square deviation of values from their average.
Where  = Sum of observations
xi = Mean or arithmetic average (x / n)
x = Individual observed value
x – xi = Deviation of a value from the mean
n = Number of observations
1.9.3 Relative Standard Deviation (RSD)
It is defined as standard deviation expressed as the percentage of
mean.
= 	 + + …
= ∑( − )− 1
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= × 100
Where
SD = Standard deviation
xi = Mean or arithmetic average (x / n)
1.9.4 Correlation Co-Efficient (R)
The correlation coefficient is used to indicate the relationship of two
random variables. It provides a measure of the strength and direction of the
correlation varying from -1 to +1. Positive values indicate that the two
variables are positively correlated, meaning the two variables vary in the
same direction. Negative values indicate that the two variables are negatively
correlated, meaning the two variables vary in the contrary direction. Values
close to +1 or -1 reveal the two variables are highly related.
Where n = number of observations
x = first value
y = second value
xy = sum of products of first and second value
x = sum of first values
y = sum of second values
x2 = sum of squares of first value
= 	 (∑ ) − (∑ )(∑ )[∑ − (∑ ) ]	[[∑ − (∑ ) ]
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y2 = sum of squares of second value
1.9.5 Linear Regression
A regression is a statistical analysis assessing the association between
two variables. It is used to find the relationship between two variables.
The equation of straight line is
Where b = slope
a = intercept
Where n = number of observations
x = first value
y = second value
xy = sum of products of first and second value
x = sum of first values
y = sum of second values
x2 = sum of squares of first value
y2 = sum of squares of second value
y = a + bx
Slope (b) = [n(Σxy) - (Σx) (Σy)]/ [n(Σx2) - (Σx)2)
Intercept (a) = [(Σy)– b(Σx)]/ n
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Chapter 2: REVIEW OF LITERATURE
ZHANG et. al.,
HPLC-MS/MS method was developed and validated for the simultaneous
determination of decitabine and valdecitabine in rat plasma. The analytes
were separated on a C18 column (150mm×4.6mm,3.5μm) and a triple-
quadrupole mass spectrometer equipped with an electrospray ionization (ESI)
source was applied for detection. A clean solid-phase extraction procedure
with cation exchange cartridge was employed to extract the analytes from rat
plasma with high recovery of decitabine (>82%). The calibration curves were
linear over a concentration range of 10-10,000ng/mL for decitabine and 5-
500ng/mL for valdecitabine. The lower limit of quantitation (LLOQ) of
decitabine and valdecitabine was 10 and 5 ng/mL, respectively. The intra-day
and inter-day precisions were less than 15% and the relative error (RE) was
all within ±15%. 49
PRAKASH CHANDAR et. al.,
Fast Analysis of Decitabine Using a Solid Core HILIC Column method was
developed by prakash Chandra group by using Accucore HILIC 2.6 μm
150 mm x 3.0 mm as column, 20 mM ammonium acetate in water /
acetonitrile (5:95 v/v) as mobile phase, 0.5 mL/min flowrate and detection
was carried out at 244 nm. The decitabine was eluted at 5.30min. 50
TONGQIN et. al.,
Determination of the Content of Decitabine for Injection and Its Related
Substances by HPLC method was developed on a Shimpack VP ODS
column(250 mm×4.6 mm, 5μm) with 0.01 mol/L solution of potassium
phosphate buffer (adjust to pH 6.8 with phosphoric acid)-methanol (98:2)
as mobile phase at the flow rate of 1.0 mL/min. The detection wavelength was
set at 220 nm. The linear concentration range of decitabine was 5.028-201.12
μg/mLwith the correlation coefficient of 0.999 8. The recoveries(n=3) of low,
medium and high concentration were 99.8%, 100.2%, 99.6%, and RSD were
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0.27%, 0.51%, 0.60%, respectively. Determination of the content of three
samples were 100.6%, 99.3%, 99.5%, the related substances were 0.56%,
0.49%, 0.44%.51
GLORY HEPSIBA et. al.,
Stability indicating Reverse phase high performance liquid chromatographic
method has been developed for the quantitative analysis of Decitabine drug
present in tablet formulation and bulk drug. The HPLC separation was
achieved on Zorbax bonus C18 Column (250mm x 4.6 mm, i.d, 5 μm particle
size) with the mobile phase and detection at 254nm.The proposed method
provided linear responses within the concentration range 400-1200 μg/ml for
Decitabine and its related compounds. LOD and LOQ values for the active
substance were 0.26 and 0.8 μg/mL, respectively. Correlation coefficients (r)
of the regression equations for the impurities were greater than 0.999 in all
cases. The precision of the method was demonstrated using intra- day assay
RSD% values which were less than 1% in all instances. 52
YOUXI ZHANG et. al.,
HPLC–MS/MS method was developed and validated for the simultaneous
determination of decitabine and valdecitabine in rat plasma. The analytes
were separated on a C18 column (150 mm × 4.6 mm, 3.5 μm) and a triple-
quadrupole mass spectrometer equipped with electro spray ionization (ESI)
source was applied for detection. A clean solid-phase extraction procedure
with cation exchange cartridge was employed to extract the analytes from rat
plasma with high recovery of decitabine (>82%). The calibration curves were
linear over a concentration range of 10–10,000 ng/mL for decitabine
and 5–500 ng/mL for valdecitabine. The lower limit of quantitation (LLOQ) of
decitabine and valdecitabine was 10 and 5 ng/mL, respectively. The intra-day
and inter-day precisions were less than 15% and the relative error (RE) was
all within ±15%.53
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DRUG PROFILE
2.2 DECITABINE 48
Fig. 3.1: Chemical structure of Decitabine.
IUPAC Name: 4-amino-1-(2-6 deoxy-β-D-erythro-pentofuranosyl)-1,3,5-
triazin-2(1H)-one
Molecular Formula: C8H12N4O4
Molecular Weight: 228.21
Category: Antineoplastic.
Description: A white to off-white crystalline powder.
Solubility: Sparingly soluble in water and soluble in DMSO.
Storage: should be kept in a tightly closed container, protected from
light.
Mechanism of action:
Decitabine is believed to exert its antineoplastic effects after
phosphorylation and direct incorporation into DNA and inhibition of DNA
methyltransferase, causing hypomethylation of DNA and cellular
differentiation or apoptosis.
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Chapter 3: AIM AND PLAN OF WORK
3.1 AIM
To develop New Rapid, Precise, Accurate RP HPLC method for the
estimation of decitabine in pharmaceutical dosage form.
3.2 PLAN OF WORK
 Solubility determination of Decitabine in various solvents and buffers.
 Determine the absorption maxima of both the drugs in UV–Visible
region in different solvents/buffers and selecting the solvents for HPLC
method development.
 Optimize the mobile phase and flow rates for proper resolution and
retention times.
 Validate the developed method as per ICH guidelines.
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4. MATERIALS AND METHODS
4.1 MATERIALS
Instruments
Table 4.1: Instruments used.
UV-Visible Spectrophotometer Analytical Technologies Ltd
HPLC Cyberlab (Salo Terrace, Millbury, USA)
Ultra Sonicator Citizen, Digital Ultrasonic Cleaner
pH meter Elico
Electronic balance Shimadzu
Syringe Hamilton
HPLC Column Develosil Rp Aqueous-AR-5 (150 x 4.6 mm ,5µm)
Chemicals
Table 4.2: Chemicals and Solvents used.
Ammonium Acetate Rankem/ AR Grade
Acetonitrile Merck/ HPLC Grade
Water Merck/ HPLC Grade
Methanol Merck/ HPLC Grade
Ortho phosphoric acid Rankem/ AR Grade
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Drug samples
Table 4.3: Drugs used.
Decitabine bulk drugs Gift samples obtained from NatcoPharma Ltd, HYD
Decitabine dosage form Obtained from local pharmacy
4.2 METHODS
Preparation of Ammonium Acetate buffer pH 4.5:
3.85 gm of Ammonium Acetate was weighed and dissolved in 1000 mL
of water. Adjust the pH to 4.5  0.02 using ortho phosphoric acid. The buffer
was filtered through 0.45µm filters to remove all fine particles and gases.
Preparation of mobile phase:
The mobile phase was prepared by mixing the buffer and acetonitrile in the
ratio of 985:15, sonicate for 5 min. ofter the solution was filtered through
0.45µm to remove all fine particles and gases.
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Chapter 5: RESULTS AND DISCUSSIONS
5.1 Solubility Studies
These studies are carried out at 25 0C
Table 4.1: Solubility studies.
5.2 Determination of Working Wavelength (λmax)
In simultaneous estimation of  two drugs isobestic wavelength is used.
Isobestic point is the wavelength where the molar absorptivity is the same for two
substances that are interconvertible. So this wavelength is used in simultaneous
estimation to estimate both drugs accurately.
5.2.1 Preparation of Standard solution
About 100 mg of decitabine weighed into a 100 mL volumetric flask, to this
25 mL of mobile phase was added, sonicated and the volume was made up to
mark with the mobile phase.
5.2.2 Dilutions
Necessary dilutions are made from standard stock solutions to get the
concentration range of 100 µg/mL of decitabine.
The wavelength of maximum absorption (λ max) of the solution of the drugs
in mobile phase were scanned using UV-Visible spectrophotometer within the
wavelength region of 200–400 nm against mobile phase as blank. The absorption
Solvent Name Decitabine
Water Soluble
DMSO Freely Soluble
Ethanol Sparingly Soluble
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curve shows characteristic absorption maxima at 244 nm for decitabine
(Fig.5.1).Thus 255 nm was selected as detector wavelength for the HPLC
chromatographic method.
Fig. 5.1: UV-VIS Spectrum of Decitabine
5.3 METHOD DEVELOPMENT FOR ASSAY
Trial -1
Chromatographic conditions
Column : Develosil Rp Aqueous-AR-5 (150 x 4.6 mm , 5 µm)
Elution mode : Isocratic
Mobile phase :          phosphate buffer pH 6.5: ACN [40:60]
Flow rate : 1.0 mL /min
Detection wavelength : 226 nm
Injection volume : 20 µL
Run time : 7 min
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Above conditions mixed standard solution is used for recording chromatogram
(Fig. 5.2.).
Fig. 5.2: Chromatogram of Trail 1
Table 5.2: Results for Trail 1
Observation
The two peaks are not well resolved. Resolution was found to be less than 2
(Table 5.2). So this trial is not considered.
Trial -2
Chromatographic conditions
Column : Develosil Rp Aqueous-AR-5 (150 x 4.6 mm , 5 µm)
Elution mode : Isocratic
Mobile phase : ACN:Methanol: Buffer pH 5 (20:40:40)
S.NO Name RT Area TP TF
1 Decitabine 4.156 2145991 2067 1.62
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Flow rate : 1.0 mL/min
Detection wavelength : 228 nm
Injection volume : 20 µL
Run time : 9 min
Mixed standard solution is used for recording chromatogram.
Fig.5.3: Chromatogram of Trail 2
Table 5.3: Results for Trail 2
Observation
It was observed that theoretical plates are very low. So this trial was not
considered.
S.NO Name RT Area TP TF
1 Decitabine 7.880 2032510 805 0.84
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Trial -3
Chromatographic conditions
Column : Develosil Rp Aqueous-AR-5 (150 x 4.6 mm , 5 µm)
Elution mode : Isocratic
Mobile phase : Ammonium Acetate buffer pH4.5: Acetonitrile (985:15)
Flow rate : 1.5 mL/min
Detection wavelength : 244 nm
Injection volume : 20 µL
Run time : 10 min
Mixed standard solution is used for recording chromatogram.
Fig. 5.4: Chromatogram of Trail 3
Table 5.4: Results for Trail 3
S.NO Name RT Area TP TF
1 Decitabine 3.410 2001568 3396 1.51
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Observation
The decitabine peak was observed at 3.410 min with peak area 2001568,
theoretical plates 3396 and tailing factor 1.51. The Theoritical plates, tailing factor
and resolution were found to be within limits. So this trail was considered and
validated according to ICH guidelines.
Conclusion: Hence this method was finalized for the estimation of decitabine.
5.4 OPTIMIZED CHROMATOGRAPHIC CONDITIONS FOR ASSAY
Table 5.5: Optimised condition.
Mobile phase Ammonium Acetate buffer pH 4.5:ACN (985:15)
Column Develosil Rp Aqueous-AR-5 (150 x 4.6 mm , 5 µm)
Flow rate 1.5 mL/min
Column temperature Room temperature(20-25oC)
Sample temperature Room temperature(20-25oC)
Wavelength 244 nm
Injection volume 20 µL
Run time 5 min
Retention time 3.401 min for decitabine
Preparation of samples for Assay
Preparation of Standard solution
About 100 mg of decitabine was weighed into a 100 mL volumetric flask, to
this 25mL of mobile phase was added, sonicated and the volume was made up
with the mobile phase.
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Preparation of Sample solution
Sample name :  Decogen
Manufacture name : Pfizer
Weigh a quantity of powder equivalent to 100 mg of decitabine in 100 mL
volumetric flask and make up mark with mobile phase. From above solution Pipette
1 mL of the clear solution in to 10 mL volumetric flask and make up volume with
mobile phase. The resulting solution is used to record the chromatogram (Fig. 7.9).
%	Assay = × WS × DT × P100 × AW × 100
Where,
AS:  Average peak area due to standard preparation
AT:  Peak area due to assay preparation
WS: Weight of decitabine in mg
WT: Weight of sample in assay preparation
DT: Dilution of assay preparation
DS: Dilution of standard preparation
P: Purity of decitabine
AV: Average weight of tablets in mg
LC: Labelled claim of decitabine
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Fig. 5.5: Chromatogram of Decitabine.
Table 5.6: Results for Decitabine.
Table 5.7: Results of assay
Drug Label claim(mg) Amountfound(mg) % Assay
Decitabine 50 49.95 99.9
Observation
So the % assay found to be within the limits. The percentage purity of
Decitabine was found to be within the limits that is 98-102 %.
S.NO Name RT Area TP TF
1 decitabine 3.653 345505 6599 1.18
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5.5 HPLC METHOD VALIDATION
5.5.1 System Suitability
To verify that the analytical system is working properly and can give
accurate and precise results were evaluated by 100 µg/mL of Decitabine was
injected six times and the chromatograms were recorded for the same.
Table 5.8: Results for system suitability of decitabine.
Injection RT Peak area Theoreticalplates (TP)
Tailing factor
(TF)
1 3.793 345849 6679 1.22
2 3.799 345177 6441 1.23
3 3.72 344045 6552 1.22
4 3.726 345849 6551 1.24
5 3.797 347590 6283 1.21
6 3.799 345784 6329 1.23
Mean 3.772333 345715.7 - -
SD 0.038323 1151.924 - -
%RSD 1.015901 0.3332 --
Acceptance criteria
1. The % RSD for the retention times of decitabine Peaks from 6 replicate
injections of each Standard solution should be not more than 2.0
2. The % RSD for the peak area responses of decitabine peaks from 6 replicate
injections of each standard solution should be not more than 2.0%.
3. The number of theoretical plates (N) for the decitabine peaks is not less than
2000.
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4. The Tailing factor (TP) for the decitabine peak is not more than 2.0.
Result
The plate count and tailing factor results were found to be satisfactory and are
found to be within the limit. The % RSD was found to be 0.33.
5.5.2 Precision
5.5.2.1 System precision
The system precision was determined by analysing standard preparation of
decitabine for six times. The chromatograms were recorded and the results were
summarized in Table 5.6.
Fig. 5.6: List of Chromatograms for system precision
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Table 5.9: Results for system precision
Injection
Decitabine
Retention
times Area TP TF
1 3.793 345849 6679 1.22
2 3.799 345177 6441 1.23
3 3.72 344045 6552 1.22
4 3.726 345849 6551 1.24
5 3.797 347590 6283 1.21
6 3.799 345784 6329 1.23
Average 3.772333 345715.7 6472.5 1.225
SD 0.038323 1151.924 - -
%RSD 1.015901 0.3332 - -
Result
% RSD of 6 determinations of decitabine for System precision found to be
within the acceptance criteria of less than 2.0%.
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5.5.2.2 Method precision
Method precision was determined by injecting sample solutions of
concentration decitabine (100 μg/mL) for six times are prepared separately.
The chromatograms were recorded and the results were summarized in
Table 5.10.
Fig. 5.7: List of Chromatograms for method precision
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Table 5.10: Results for method precision
Injection
Decitabine
Retention
times Area TP TF
1 3.74 345746 6883 1.25
2 3.758 344016 6140 1.23
3 3.795 347992 6829 1.22
4 3.763 346110 6874 1.22
5 3.712 345853 6822 1.21
6 3.73 345690 6932 1.22
Average 3.749667 345901.2 6746.667 1.225
SD 0.028987 1268.072 - -
%RSD 0.773065 0.3666 - -
Result
The %RSD of 6 determinations of decitabine for System precision found to
be within the acceptance criteria of less than 2.0%.
5.5.3 Linearity and range
Preparation of standard stock solution
Standard stock solutions of decitabine (mg/mL) were prepared by
dissolving 100 mg of decitabine in 100 mL of mobile phase. After that filtered
the solution using 0.45-micron syringe filter and Sonicated for 5 min further
dilutions were given in the Table 8.17.
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Table 5.11: Linearity Preparations.
The above prepared dilutions were in injected into the system and the
chromatograms were recorded as given in Fig. 5.8, 5.9, 5.10, 5.11, 5.12 and the
results of the chromatograms are given in Tables 5.12, 5.13, 5.15, 5.15, 5.16
respectively.
Fig 5.8: Chromatogram of linearity for preparation 1.
Preparations
Volume
from
standard
stock
transferred
in mL
Volume
made up in
mL (with
mobile
phase)
Conc.
obtained
(µg/mL)
Decitabine
Preparation 1 0.5 10 50
Preparation 2 0.7 10 70
Preparation 3 1 10 100
Preparation 4 1.2 10 120
Preparation 5 1.5 10 150
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Table 5.12: Results for preparation 1.
Fig 5.9: Chromatogram of linearity for preparation 2.
Table 5.13: Results for preparation 2.
Fig 5.10: Chromatogram of linearity for preparation 3.
S.NO Name RT Area TP TF
1 Decitabine 3.768 174482 4317 1.24
S.NO Name RT Area TP TF
1 Decitabine 3.786 232730 4107 1.24
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Table 5.14: Results for preparation 3.
Fig 5.11: Chromatogram of linearity for preparation 4.
Table 5.15: Results for preparation 4.
Fig 5.12: Chromatogram of linearity for preparation 5.
S.NO Name RT Area TP TF
1 Decitabine 3.706 345818 6334 1.24
S.NO Name RT Area TP TF
1 Decitabine 3.796 423221 6019 1.20
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Table 5.16: Results for preparation 5.
A graph was plotted against the concentrations of the solutions and the
peak areas (Table 8.17). The correlation coefficient R2 was determined and was
found to be 0.998 (Fig. 8.13).
Table 5.17: Linearity data of Decitabine.
Fig 5.13: Graph for Linearity data of Decitabine.
y = 3515.x - 5526.
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Linearity of Decitabine
S.NO Name RT Area TP TF
1 Decitabine 3.794 518543 6623 1.20
S.No Concentration (µg/mL) Area
1 50 174482
2 70 232730
3 100 345818
4 120 423221
5 150 518543
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Table 5.18: Observation for linearity.
Acceptance criteria
The relationship between the concentration (in %) and area of decitabine
should be linear in the specified range and the correlation should not be less than
0.99.
Result
The correlation coefficient for linear curve obtained between concentration
vs. Area for standard preparations of decitabine was found to be 0.998
respectively.
5.5.4 Limit of Detection and Limit of Quantitation
LOD and LOQ is calculated from standard deviation of response from
precision and slope from linearity
LOQ = 10 σ / S
LOD = 3.3 σ / S
Where
σ is standard deviation from response
S is slope from calibration curve
The LOD for this method was found to be 0.0003 µg/mL. The LOQ for this
method was found to be 0.0009 µg/mL.
S.No Parameter Decitabine
1 Correlation coefficient 0.998
2 Slope 3515
3 Intercept 5526
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5.5.5 Specificity
The standard solution 100 μg/mL of decitabine was injected and the
chromatogram was recorded for the same as given in Fig. 5.14.
The sample solution 100 μg/mL of decitabine was injected and the
chromatogram was recorded for the same as given in Fig. 5.15.
Fig 5.14: Chromatogram of standard.
Table 5.19: Results for standard.
S.NO Name RT Area TP TF
1 Decitabine 3.793 345849 6679 1.22
Fig 5.15: Chromatogram of formulation.
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Table 5.20: Results for formulation.
Result
It was observed that diluent or excipient peaks do not interfere with analyte
peak.
5.5.6 Accuracy
Accuracy of the method was determined by Recovery studies. To the
formulation (pre analysed sample), the reference standards of the drugs were
added at the level of 50%, 100%, 150%. The recovery studies were carried out
three times and the percentage recovery and percentage mean recovery were
calculated for drug is shown in Table 8.24.
Fig 5.16: Chromatogram of 50% recovery
Table 5.21: Results for 50% Recovery.
S.NO Name RT Area TP TF
1 Decitabine 3.795 172873 6241 1.26
S.NO Name RT Area TP TF
1 Decitabine 3.653 345505 6599 1.18
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Fig 5.17: Chromatogram of 100% recovery
Table 5.22: Results for 100% Recovery.
S.NO Name RT Area TP TF
1 Decitabine 3.770 344556 6395 1.11
Fig 5.18: Chromatogram of 150% Recovery.
Table 5.23: Results for 150% Recovery.
S.NO Name RT Area TP TF
1 Decitabine 3.751 518619 6732 1.06
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Table 5.24: Results for Recovery of Decitabine.
* Mean of three observations
Acceptance criteria
The % recovery of Decitabine should lie between 98% and 102%.
Result
The percentage mean recovery of Decitabine was found to be 99.77%
respectively.
5.5.7 Robustness
The Robustness of the method was determined. The results obtained by
deliberate variation in method parameters are summarized below in Table 5.29.
Fig. 5.19: Chromatogram of mobile phase composition 987:13.
Conc Amount
present
(µg/mL)
Amount
added
(µg/mL)
Amount
found
(µg/mL)*
Percent
Recovery
*
% Mean
Recovery
50% 40 10 49.56 99.13
99.77100% 90 10 100.02 100.02
150% 140 10 150.27 100.18
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Table 5.25: Results of mobile phase composition 987:13.
S.NO Name RT Area TP TF
1 Decitabine 3.728 343650 6027 1.05
Fig.5.20: Chromatogram of mobile phase composition 983:17.
Table 5.26: Results of mobile phase composition 983:17.
S.NO Name RT Area TP TF
1 Decitabine 3.751 344556 6732 1.06
Fig. 5.21: Chromatogram of wavelength from 244 to 246 nm.
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Table 5.27: Results of wavelength from 244 to 246 nm.
S.NO Name RT Area TP TF
1 Decitabine 3.770 344556 6395 1.11
Fig. 5.22: Chromatogram of wavelength from 244 to 242 nm.
Table 5.28: Results of wavelength from 244 to 242 nm.
Table 5.29: Results for Robustness of Decitabine.
Chromatographic changes Retention
time(min)
Tailing factor
wavelength
(nm)
242 3.783 1.07
244 3.768 1.24
246 3.770 1.11
Mobile phase
composition(v/v)
983:18 3.751 1.06
985:15 3.768 1.24
987:13 3.728 1.05
S.NO Name RT Area TP TF
1 Decitabine 3.783 345432 6459 1.07
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Result
The tailing factor was found to be within the limits on small variation of
flow rate and wavelength.
Chapter-VI SUMMARY AND CONCLUSION
Page 72
PChapter 6: SUMMARY
Each and every day a number of diseases are being diagnosed.
Several cancer diseases are on a rise not only for the rich but also for the
poor. So, various pharmaceutical organizations are working to develop new
drug molecules and new combinations of anticancer drugs for better
treatment. This is the reason for a greater competition in the pharmaceutical
sector, and the future scenario is likely to be the same.
The scope of developing and validating a method is to ensure a
suitable strategy for evaluation of a particular analyte which is more specific,
accurate and precise. The main focus is drawn to achieve improvement in the
manufacturing and analytical conditions and making proper amendments in
the standard operating procedures being followed.
The above review indicates that there are fewer methods for the
estimation of Decitabine in pharmaceutical formulations. But the buffers used
in this method was at acidic pH which may affect the column life and some
method were with more a run time. So my aim was to develop a new method
with minimum run time and less solvent consumption for the estimation of
Decitabine in combination of drugs. Hence the present study aims to develop
rapid, precise and accurate methods for the determination of Decitabine by
RP-HPLC in pharmaceutical dosage forms.
CONCLUSION
A new precise, accurate, rapid method has been developed for the
simultaneous estimation of Decitabine in pharmaceutical dosage form by RP-
HPLC.
The optimum wavelength for the determination of Decitabine was
selected at 244 nm. Various trials were performed with different mobile
phases in different ratios, but Ammonium Acetate buffer pH 4.5: ACN (985:15)
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was selected as good peak symmetry. The Retention time of decitabine was
found to be 3.786 min.
The different analytical performance parameters such as linearity,
precision, accuracy, and specificity, LOD, LOQ were determined according to
International Conference on Harmonization ICH Q2B guidelines. The
calibration curves were obtained by plotting peak area versus the
concentration over the range of 50-150 µg/mL. From linearity the
correlation coefficient R2 value was found to be 0.998. The proposed HPLC
method was also validated for system suitability, system precision and
method precision. The % RSD in the peak area of drug was found to be less
than 2%. The number of theoretical plates was found to be more than 2000,
which indicates efficient performance of the column. The LOD for this method
was found to be 0.0003µg/mL. The LOQ for this method was found to be
0.0009 µg/mL, indicates the sensitivity of the method. The percentage of
recovery of was found to be 99.77 shows that the proposed method is highly
accurate.
Hence the proposed method is highly sensitive, precise and accurate
and it successfully applied for the quantification of API content in the
commercial formulations of decitabine in Educational institutions and Quality
control laboratories.
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